Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Launched by BRISTOL-MYERS SQUIBB · Apr 9, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at tumor samples from patients who have received a special type of treatment called gene modified cell therapy made by Bristol-Myers Squibb. The goal of the study is to check the levels of specific genes in these tumors, particularly in patients who have developed a second type of cancer after their treatment. The conditions being studied include Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, and Multiple Myeloma.

To be eligible for this trial, participants must have received the Bristol-Myers Squibb gene modified cell therapy and have been diagnosed with a second primary cancer that meets the study's criteria. However, if someone is currently in another clinical trial or hasn't received this specific therapy, they won't be able to participate. Those who join the trial can expect to provide tumor samples for testing, which will help researchers understand more about how this therapy works and its effects on other cancers. This study is currently recruiting participants of all ages and genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
• • Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
• Exclusion Criteria:
• • Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.
• • Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.